Join Growin Stock Community!

Charles river laboratories international, inc.CRL.US Overview

US StockHealthcare
(No presentation for CRL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CRL AI Insights

CRL Overall Performance

CRL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRL Recent Performance

-0.17%

Charles river laboratories international, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CRL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CRL Key Information

CRL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CRL Profile

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Price of CRL

CRL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.93
PE Ratio (TTM)
-
Forward PE
17.25
PS Ratio (TTM)
2.19
PB Ratio
2.54
Price-to-FCF
16.91
METRIC
VALUE
vs. INDUSTRY
Gross Margin
32.96%
Net Margin
-3.59%
Revenue Growth (YoY)
-0.85%
Profit Growth (YoY)
-0.64%
3-Year Revenue Growth
-3.31%
3-Year Profit Growth
-8.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.93
PE Ratio (TTM)
-
Forward PE
17.25
PS Ratio (TTM)
2.19
PB Ratio
2.54
Price-to-FCF
16.91
Gross Margin
32.96%
Net Margin
-3.59%
Revenue Growth (YoY)
-0.85%
Profit Growth (YoY)
-0.64%
3-Year Revenue Growth
-3.31%
3-Year Profit Growth
-8.09%

  • When is CRL's latest earnings report released?

    The most recent financial report for Charles river laboratories international, inc. (CRL) covers the period of 2025Q4 and was published on 2025/12/27. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRL's short-term business performance and financial health. For the latest updates on CRL's earnings releases, visit this page regularly.

  • What is the operating profit of CRL?

    According to the latest financial report, Charles river laboratories international, inc. (CRL) reported an Operating Profit of -283.44M with an Operating Margin of -28.51% this period, representing a decline of 69.03% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CRL's revenue growth?

    In the latest financial report, Charles river laboratories international, inc. (CRL) announced revenue of 994.23M, with a Year-Over-Year growth rate of -0.83%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does CRL have?

    At the end of the period, Charles river laboratories international, inc. (CRL) held Total Cash and Cash Equivalents of 213.77M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CRL go with three margins increasing?

    In the latest report, Charles river laboratories international, inc. (CRL) did not achieve the “three margins increasing” benchmark, with a gross margin of 31.1%%, operating margin of -28.51%%, and net margin of -27.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CRL's profit trajectory and future growth potential.

  • Is CRL's EPS continuing to grow?

    According to the past four quarterly reports, Charles river laboratories international, inc. (CRL)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -5.57. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRL?

    Charles river laboratories international, inc. (CRL)'s Free Cash Flow (FCF) for the period is 58.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 30.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CRL?

    The latest valuation data shows Charles river laboratories international, inc. (CRL) has a Price-To-Earnings (PE) ratio of -53.89 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.